Stevanato Group S.p.A.

Vertiva™ is an on-body delivery system platform composed of a single-use pod with pre-filled and pre-loaded cartridge and a multi-use, smart controller. The device is able to deliver micro-precision basal doses and full-content bolus injections, resulting in a highly flexible,...

Alba® represents a best-in-class solution to address the development of sensitive biologics, such as highly concentrated drugs prone to silicone aggression and ophthalmic drugs. Medicines are particularly sensitive to all the components of the primary packaging they are in contact with,...

Many Pharmaceutical companies are looking for ways to lower their footprint and reduce total costs by relying on experienced external partners for non-core activities. When it comes to containment solutions for biopharmaceutical products, no solution matches SG EZ-fill®, whose proven advan...

Owen Mumford's device expertise is joining forces with Stevanato Group's unique engineering and manufacturing experience. The collaboration brings the full value of the Aidaptus® auto-injector platform to the market, helping patients self-administer their therapy using a simple and easy-to-use device. ...

MAVIS Platform is our latest innovative suite for best-in-class inspection results.Developed to match every drug perfectly, MAVIS Platform guarantees easy and accessible operations for maintenance and control. It combines advanced inspection performances with a small footprint.

Platform Highligh...

Paris once again welcomes Europe’s leading trade show in pharmaceutical packaging and drug delivery innovation. Join our content team as Pharmapack 2024 opens its doors to leading experts and innovators in pharmaceutical packaging and drug delivery. 

Lars Keinicke Hansen, Chiara Mussoi, and Odra Pinato, all of Stevanato Group, describe how the streamlining of processes and harmonisation of products and services can better serve pharmaceutical companies. A case study highlights how a unique combination of expertise in automation and glass primary packaging benefited pharma giant Merck Serono in a recent project.

Advances in auto-injector design now provide the option to use both 1ml and 2.25mL syringes plus employ technology to adapt to varying fill volumes and viscosities all whilst maintaining the same device form. This provides a solution for the formulation changes that take place during drug development, clinical trials, and life cycle management. When looking at the performance of any parenteral injection device, the drug containment systems play a crucial role. Auto-injector performance and functionality is strictly linked to key dimensional tolerances of glass syringes. We will illustrate the importance of syringe design to ensure these requirements and how monitoring dimensional parameters at an early stage of the development is key to ensure the intended use and ultimately work to preserve patients’ safety. Benefits of tight collaboration between device designer and manufacturer will also be discussed.